98586-21-1Relevant articles and documents
Temperature-controlled divergent synthesis of 4-alkoxy- or 4-alkenyl-chromanes via inverse electron-demand cycloaddition with in situ generated ortho-quinone methides
Tanaka, Kenta,Kishimoto, Mami,Hoshino, Yujiro,Honda, Kiyoshi
supporting information, p. 1841 - 1845 (2018/04/11)
The temperature-controlled divergent synthesis of 4-alkoxy- or 4-alkenyl-chromanes via inverse electron-demand cycloaddition with in situ generated ortho-quinone methides under identical reaction conditions except for thermal condition has been developed. At room temperature, the reaction generated 4-methoxychromanes, whereas the reaction performed at room temperature to 100 °C gave 4-alkenylchromanes. Trifluoromethanesulfonic acid was efficiently suitable in the reaction to give the 4-substituted chromanes. This divergent synthetic strategy exhibits a new method giving carbon–carbon or carbon–oxygen bond by controlling the reaction temperature.
Kinetics of the solvolyses of fluoro-substituted benzhydryl derivatives: Reference electrofuges for the development of a comprehensive nucleofugality scale
Nolte, Christoph,Mayr, Herbert
supporting information; experimental part, p. 1435 - 1439 (2010/05/18)
A series of m-fluoro-substituted benzhydryl chloridcjs, bromides, mesylates and Losylates 1-X to 5-X were prepared and subjected to solvolysis reactions in various solvents. The observed first-order rate constants ks(25 °C) were found to follow the correlation equation log ks(25 °C) = Sf(Nf + Ef), which allowed us to determine the electrofugalily parameters Ef for these destabilized benzhydrylium cations and the nucleofugality parameters Nf, S f for a series of leaving group/ solvent combinations.
MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF
-
Page/Page column 103, (2008/12/07)
Provided are compounds that are modulators of C3a receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, the compounds are pyridones. In certain embodiments, provided are methods for treatment or amelioration of diseases associated with modulation of C3a receptor activity.